Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

Amid its multi-front legal battle with Apple over its smartwatch’s blood oxygen sensors, Masimo has claimed new ...

After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit ...

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will ...

Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path ...

Beacon Biosignals, known for its sleep monitoring system, hauled in $86 million as part of an oversubscribed series B funding ...

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...

Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with ...

One in four safety-related failures are due to central nervous system (CNS) toxicity. | One in four safety-related failures are due to central nervous system (CNS) toxicity.

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

After celebrating a 1 billion-euro-plus fundraising accomplishment back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.< | ...